Pancreatic Cancer Research

ResearcherUniversità Cattolica del Sacro CuoreActive in the last 2 years

Sergio Alfieri

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7813-4426; OpenAlex author ID A5039218536. Sources: OpenAlex.

Their work

Papers
28 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
90
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 3 papers · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 6 papers · 2024: 6 papers · 2025: 2 papers · 2026: 4 papers

Papers 28

  1. Designing a national network of pancreas units: the Italian model for high-quality pancreatic cancer care. Co-author DOI 10.1007/s13304-026-02598-7↗
  2. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  3. ASO Visual Abstract: Survival Benefit of Surgery Versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18479-z↗
  4. Preoperative Biliary Drainage with Metal Stent Versus Early Surgery in Patients with Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1245/s10434-026-19546-9↗
  5. Surgical treatment of synchronous liver-only oligometastatic pancreatic adenocarcinoma: a systematic review and meta-analysis of long-term outcomes. Co-author DOI 10.1097/js9.0000000000002338↗
  6. Survival Benefit of Surgery versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18212-w↗
  7. Minimally invasive versus open radical antegrade modular pancreatosplenectomy for pancreatic ductal adenocarcinoma: an entropy balancing analysis. Co-author DOI 10.1016/j.hpb.2023.09.013↗
  8. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2024.101411↗
  9. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  10. Combined Nabpaclitaxel pressurized intraPeritoneal aerosol chemotherapy with systemic Nabpaclitaxel-Gemcitabine chemotherapy for pancreatic cancer peritoneal m… Co-author DOI 10.1515/pp-2024-0010↗
  11. The Past, Present, and Future of Biomarkers for the Early Diagnosis of Pancreatic Cancer. Co-author DOI 10.3390/biomedicines12122840↗
  12. Understanding the Conundrum of Pancreatic Cancer in the Omics Sciences Era. Co-author DOI 10.3390/ijms25147623↗
  13. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
  14. Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer. Co-author DOI 10.1186/s12967-023-04733-z↗
  15. The role of the multidisciplinary tumor board (MDTB) in the assessment of pancreatic cancer diagnosis and resectability: A tertiary referral center experience. Last author DOI 10.3389/fsurg.2023.1119557↗
  16. The Role of Microbiota in Pancreatic Cancer. Co-author DOI 10.3390/cancers15123143↗
  17. Immunohistochemical Evaluation of the Expression of Specific Membrane Antigens in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15184586↗
  18. Nutritional Interventions during Chemotherapy for Pancreatic Cancer: A Systematic Review of Prospective Studies. Co-author DOI 10.3390/nu15030727↗
  19. Role of Chemoradiation in the Adjuvant Treatment of Radically Resected Pancreatic Cancer Patients: A Mono-Institutional Retrospective Analysis. Co-author DOI 10.1159/000525945↗
  20. Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and a promising therapeutic target Co-author DOI 10.21203/rs.3.rs-2095432/v1↗
  21. Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response. Co-author DOI 10.3389/fmed.2021.793144↗
  22. Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.4240/wjgs.v13.i9.885↗
  23. Resection margin status in pancreatic cancer surgery: is it really less important than the N status? Last author DOI 10.1002/bjs.11356↗
  24. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. Co-author DOI 10.1016/j.tranon.2018.08.017↗
  25. Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. Co-author DOI 10.1186/s12885-019-5790-2↗
  26. Adjuvant Chemoradiation in Pancreatic Cancer: A Pooled Analysis in Elderly (≥75 years) Patients. Co-author PMID 26026108↗
  27. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2014.07.024↗
  28. Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma. Co-author DOI 10.1245/s10434-012-2767-7↗

Closest collaborators

The 25 strongest of 90 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giuseppe Quero · 13 shared papers, 2019–2026 · strength 2.14
  2. Giampaolo Tortora · 9 shared papers, 2021–2026 · strength 1.37
  3. Claudio Fiorillo · 5 shared papers, 2019–2025 · strength 0.90
  4. Ugo Boggi · 4 shared papers, 2024–2026 · strength 0.82
  5. Carmine Carbone · 5 shared papers, 2021–2024 · strength 0.75
  6. Riccardo Casadei · 5 shared papers, 2019–2026 · strength 0.74
  7. Lisa Salvatore · 4 shared papers, 2022–2024 · strength 0.64
  8. Emanuele F. Kauffmann · 3 shared papers, 2024–2026 · strength 0.60
  9. Alessandro Zerbi · 3 shared papers, 2024–2026 · strength 0.60
  10. Federica Vitale · 3 shared papers, 2023–2024 · strength 0.56
  11. Lorenzo Zileri Dal Verme · 3 shared papers, 2023–2024 · strength 0.56
  12. Alberto Nicoletti · 3 shared papers, 2023–2024 · strength 0.56
  13. Michele Reni · 5 shared papers, 2014–2026 · strength 0.43
  14. Allegra Ripolli · 2 shared papers, 2025–2026 · strength 0.41
  15. Kongyuan Wei · 2 shared papers, 2025–2026 · strength 0.41
  16. V. Egorov · 2 shared papers, 2025–2026 · strength 0.41
  17. Gregory G. Tsiotos · 2 shared papers, 2025–2026 · strength 0.41
  18. Yuichi Nagakawa · 2 shared papers, 2025–2026 · strength 0.41
  19. Niccolò Napoli · 2 shared papers, 2025–2026 · strength 0.41
  20. Benedetto Ielpo · 2 shared papers, 2025–2026 · strength 0.41
  21. Elena B. Rangelova · 2 shared papers, 2025–2026 · strength 0.41
  22. Emilio Vicente · 2 shared papers, 2025–2026 · strength 0.41
  23. Marc G. Besselink · 2 shared papers, 2025–2026 · strength 0.41
  24. Giuseppe Fusai · 2 shared papers, 2025–2026 · strength 0.41
  25. Roberto Coppola · 2 shared papers, 2025–2026 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.